Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KeY Treat
NCT03949764Phase 4Completed
- Start
- Sep 2019
- Primary completion
- Jun 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir + velpatasvir in hepatitis C (HCV) (2 arms). Primary endpoints: Participants Who Started HCV Treatment at 12 weeks, Participants Who Completed Treatment at 24 weeks and 2 more. Started Sep 2019; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03949764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949764.